Lung Cancer最新文献_第2页

Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials 参与肺癌生物标本研究：ECOG-ACRIN 3期E1505和E5508临床试验分析

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-07 DOI: 10.1016/j.lungcan.2026.109304

Yating Wang , Zhuoxin Sun , Arthi Sridhar , Suresh S. Ramalingam , Heather A. Wakelee , David E. Gerber

Background

Biospecimen analyses may provide important insights into patient selection and pharmacodynamic effects. To provide generalizable findings, such studies must enroll adequate and diverse populations.

Methods

We analyzed patient and institutional characteristics according to agreement to participate in optional, embedded biospecimen studies among patients enrolled in the E1505 and E5508 phase 3 lung cancer therapeutic trials. Differences were compared using Wilcoxon rank sum test, Pearson’s Chi-squared test, and logistic regression.

Results

Overall, 3,017 patients were enrolled in the two trials. Mean age was 63 years, 49% were female, and 83% were non-Hispanic white. Among these individuals, 2,692 (89%) agreed to participate in at least one biospecimen study, and 2,577 (85%) agreed to studies requiring future biospecimen collection. In multivariable logistic regression, compared to non-Hispanic white patients, other patients were less likely to agree to participate: OR 0.59 (95% CI, 0.45–0.79; P < 0.001) for any biospecimen study; OR 0.62 (95% CI, 0.48–0.80; P < 0.001) for studies requiring future biospecimen collection. Women and patients treated outside main academic institutions (e.g., affiliates, community sites) were also less likely to participate.

Conclusions

Among patients enrolled in lung cancer clinical trials, women, racial and ethnic minorities, and patients treated outside major academic centers are less likely to participate in optional biospecimen studies. Because some of these populations may already be under-represented in trial populations, this pattern may exacerbate disparities in translational and clinical research.

Trial registration: NCT00324805, NCT01107626.

生物标本分析可以为患者选择和药效学效应提供重要的见解。为了提供可推广的发现，这些研究必须纳入足够和多样化的人群。方法根据参与E1505和E5508 3期肺癌治疗试验的可选、嵌入生物标本研究的协议，分析患者和机构特征。采用Wilcoxon秩和检验、Pearson卡方检验和logistic回归比较差异。结果两项试验共纳入3017例患者。平均年龄63岁，49%为女性，83%为非西班牙裔白人。在这些人中，2692人（89%）同意参加至少一项生物标本研究，2577人（85%）同意未来需要收集生物标本的研究。在多变量logistic回归中，与非西班牙裔白人患者相比，其他患者同意参与的可能性较小：任何生物标本研究的OR为0.59 (95% CI, 0.45-0.79; P < 0.001)；对于需要未来收集生物标本的研究，OR为0.62 （95% CI, 0.48-0.80; P < 0.001）。在主要学术机构（例如附属机构、社区站点）以外接受治疗的妇女和患者也不太可能参与。在参加肺癌临床试验的患者中，女性、种族和少数民族以及在主要学术中心以外接受治疗的患者不太可能参加可选的生物标本研究。由于其中一些人群在试验人群中的代表性不足，这种模式可能会加剧转化和临床研究中的差异。试验注册号：NCT00324805， NCT01107626。

{"title":"Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials","authors":"Yating Wang , Zhuoxin Sun , Arthi Sridhar , Suresh S. Ramalingam , Heather A. Wakelee , David E. Gerber","doi":"10.1016/j.lungcan.2026.109304","DOIUrl":"10.1016/j.lungcan.2026.109304","url":null,"abstract":"<div><h3>Background</h3><div>Biospecimen analyses may provide important insights into patient selection and pharmacodynamic effects. To provide generalizable findings, such studies must enroll adequate and diverse populations.</div></div><div><h3>Methods</h3><div>We analyzed patient and institutional characteristics according to agreement to participate in optional, embedded biospecimen studies among patients enrolled in the E1505 and E5508 phase 3 lung cancer therapeutic trials. Differences were compared using Wilcoxon rank sum test, Pearson’s Chi-squared test, and logistic regression.</div></div><div><h3>Results</h3><div>Overall, 3,017 patients were enrolled in the two trials. Mean age was 63 years, 49% were female, and 83% were non-Hispanic white. Among these individuals, 2,692 (89%) agreed to participate in at least one biospecimen study, and 2,577 (85%) agreed to studies requiring future biospecimen collection. In multivariable logistic regression, compared to non-Hispanic white patients, other patients were less likely to agree to participate: OR 0.59 (95% CI, 0.45–0.79; <em>P</em> < 0.001) for any biospecimen study; OR 0.62 (95% CI, 0.48–0.80; <em>P</em> < 0.001) for studies requiring future biospecimen collection. Women and patients treated outside main academic institutions (e.g., affiliates, community sites) were also less likely to participate.</div></div><div><h3>Conclusions</h3><div>Among patients enrolled in lung cancer clinical trials, women, racial and ethnic minorities, and patients treated outside major academic centers are less likely to participate in optional biospecimen studies. Because some of these populations may already be under-represented in trial populations, this pattern may exacerbate disparities in translational and clinical research.</div><div><strong>Trial registration:</strong> NCT00324805, NCT01107626.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109304"},"PeriodicalIF":4.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting 一线lenvatinib治疗晚期或复发性胸腺癌的疗效和安全性

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-07 DOI: 10.1016/j.lungcan.2026.109309

Ryosuke Tsugitomi , Kento Takagi , Go Saito , Motoko Tachihara , Hironori Ashinuma , Takehito Shukuya , Shinnosuke Takemoto , Shinya Sakata , Atsuto Mouri , Hideki Miwa , Yosuke Tamura , Takaaki Tokito , Yoko Tsukita , Yoshihito Kogure , Takeshi Masuda , Hiroshi Tanaka , Sousuke Kubo , Takaaki Sasaki , Tomohiro Oba , Nobuaki Mamesaya , Takuji Suzuki

Background

Thymic carcinoma is a rare thoracic malignancy with limited first-line treatment options. Lenvatinib has shown efficacy and tolerability in previously treated patients, but its role in chemotherapy-naive patients is unclear.

Methods

We conducted a retrospective, multicentre observational study across 31 Japanese institutions. Patients with advanced or recurrent thymic carcinoma who received lenvatinib between 23 March 2021 and 31 October 2022 were included. Data cut-off was 13 November 2024. Outcomes for chemotherapy-naive patients included objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and adverse events (AEs). Subgroup analyses were stratified by age.

Results

Of 107 patients, 20 received lenvatinib as first-line therapy. Median observation was 23.6 months (interquartile range, 12.5–27.1). ORR was 50% (90% confidence interval [CI], 27.2–72.8%), and DCR 85% (95% CI, 62.1–96.8%). Median PFS, TTF, and OS were 10.9 months (95% CI, 5.6–17.1), 8.9 months (95% CI, 5.3–17.8), and 25.0 months (95% CI, 21.2–not reached). AEs occurred in 95% (Grade ≥ 3 in 60%); dose reductions and discontinuations occurred in 85% and 25%. Safety was consistent with prior reports. Older patients showed higher rates of Grade ≥ 3 AEs and discontinuation.

Conclusions

In this real-world cohort, first-line lenvatinib demonstrated favourable efficacy and manageable safety, supporting its use in advanced or recurrent thymic carcinoma.

背景：胸腺癌是一种罕见的胸部恶性肿瘤，一线治疗方案有限。Lenvatinib在先前治疗过的患者中显示出疗效和耐受性，但其在首次化疗患者中的作用尚不清楚。方法：我们在31家日本机构进行了一项回顾性、多中心观察性研究。研究纳入了在2021年3月23日至2022年10月31日期间接受lenvatinib治疗的晚期或复发性胸腺癌患者。数据截止日期为2024年11月13日。首次化疗患者的结局包括客观缓解率（ORR）、无进展生存期（PFS）、疾病控制率（DCR）、治疗失败时间（TTF）、总生存期（OS）和不良事件（ae）。亚组分析按年龄分层。结果107例患者中，20例接受lenvatinib作为一线治疗。中位观察时间为23.6个月（四分位数间距为12.5-27.1）。ORR为50%(90%置信区间[CI]， 27.2-72.8%)， DCR为85% （95% CI, 62.1-96.8%）。中位PFS、TTF和OS分别为10.9个月（95% CI, 5.6-17.1）、8.9个月（95% CI, 5.3-17.8）和25.0个月（95% CI， 21.2 -未达到）。95%发生不良事件（≥3级的发生率为60%）；剂量减少和停药的发生率分别为85%和25%。安全性与先前的报告一致。老年患者表现出更高的≥3级ae和停药率。结论：在这个现实世界的队列中，一线lenvatinib显示出良好的疗效和可管理的安全性，支持其用于晚期或复发性胸腺癌。

{"title":"Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting","authors":"Ryosuke Tsugitomi , Kento Takagi , Go Saito , Motoko Tachihara , Hironori Ashinuma , Takehito Shukuya , Shinnosuke Takemoto , Shinya Sakata , Atsuto Mouri , Hideki Miwa , Yosuke Tamura , Takaaki Tokito , Yoko Tsukita , Yoshihito Kogure , Takeshi Masuda , Hiroshi Tanaka , Sousuke Kubo , Takaaki Sasaki , Tomohiro Oba , Nobuaki Mamesaya , Takuji Suzuki","doi":"10.1016/j.lungcan.2026.109309","DOIUrl":"10.1016/j.lungcan.2026.109309","url":null,"abstract":"<div><h3>Background</h3><div>Thymic carcinoma is a rare thoracic malignancy with limited first-line treatment options. Lenvatinib has shown efficacy and tolerability in previously treated patients, but its role in chemotherapy-naive patients is unclear.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multicentre observational study across 31 Japanese institutions. Patients with advanced or recurrent thymic carcinoma who received lenvatinib between 23 March 2021 and 31 October 2022 were included. Data cut-off was 13 November 2024. Outcomes for chemotherapy-naive patients included objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), time to treatment failure (TTF), overall survival (OS), and adverse events (AEs). Subgroup analyses were stratified by age.</div></div><div><h3>Results</h3><div>Of 107 patients, 20 received lenvatinib as first-line therapy. Median observation was 23.6 months (interquartile range, 12.5–27.1). ORR was 50% (90% confidence interval [CI], 27.2–72.8%), and DCR 85% (95% CI, 62.1–96.8%). Median PFS, TTF, and OS were 10.9 months (95% CI, 5.6–17.1), 8.9 months (95% CI, 5.3–17.8), and 25.0 months (95% CI, 21.2–not reached). AEs occurred in 95% (Grade ≥ 3 in 60%); dose reductions and discontinuations occurred in 85% and 25%. Safety was consistent with prior reports. Older patients showed higher rates of Grade ≥ 3 AEs and discontinuation.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort, first-line lenvatinib demonstrated favourable efficacy and manageable safety, supporting its use in advanced or recurrent thymic carcinoma.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109309"},"PeriodicalIF":4.4,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Letter to the Editor entitled “Methodological considerations in assessing the clinical impact of TP53 classifications in advanced NSCLC” 对“评估晚期NSCLC中TP53分类的临床影响的方法学考虑”致编辑的回复

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-06 DOI: 10.1016/j.lungcan.2026.109303

Deborah Di-Xin Zhou, Chee Khoon Lee

引用次数: 0

HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma hdac1修饰的纤层蛋白A/C驱动rb1缺陷肺腺癌的核变形

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-04 DOI: 10.1016/j.lungcan.2026.109301

Hongxia Li , Yu Chen , Lihong Wei , Peng Wu , Fei Fang , Fengru Li , Bixia Liu , Shuhua Li , Qiong He , Jianwen Zhou , Kejing Tang , Zunfu Ke

Background

Lineage transformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC) represents a rare yet well-documented off-target mechanism associated with acquired resistance to tyrosine kinase inhibitors (TKIs). However, the relationship between this transformation and morphological changes remains inadequately understood. This study seeks to elucidate the molecular mechanisms by which RB1 depletion facilitates lineage transformation, with a particular emphasis on its role in morphological alterations.

Methods

Integrated molecular, morphological, and structural analyses were conducted in RB1-deficient LUAD models in vitro and in vivo. Functional perturbation and pharmacological inhibition of RB1-associated regulators were further performed to delineate the mechanism of the RB1/E2F1/HDAC1 axis.

Results

Patients with LUAD exhibiting low expression levels of TP53 and RB1 exhibited enhanced tumor invasion characteristics and a poor clinical prognosis. Our findings demonstrated that RB1 depletion induced epithelial-mesenchymal transition (EMT) characteristics in LUAD cells, as evidenced by spindle-shaped morphology, increased vimentin expression, and decreased E-cadherin expression. Furthermore, RB1 loss is responsible for nuclear abnormalities, including irregular distribution of nuclear hallmarks such as lamin A/C and emerin, which contribute to tumor aggressiveness. Through the downregulation of individual components of the RB1/E2F1/HDAC1 complex, we identified HDAC1 as a key regulatory factor influencing lamin A/C modification and nuclear deformation. Pharmacological inhibition of HDAC1 derivatives ameliorates the nuclear abnormalities observed in RB1-depleted lung cancer cells, suggesting a potential therapeutic strategy. Mechanistically, the loss of acetylated lamin A/C leads to its degradation and granular distribution, resulting in compromised nuclear mechanostability and defective cytoskeletal dynamics, which may elucidate the observed EMT.

Conclusions

Collectively, our findings suggested that the downregulation of RB1 significantly influences the morphology of LUAD by facilitating EMT and nuclear abnormalities through HDAC1-mediated deacetylation of lamin A/C. Future research should prioritize the development of targeted therapies aimed at restoring RB1 function or inhibiting HDAC1 to mitigate cancer progression, thereby enhancing patient stratification and treatment strategies in TKI-resistant LUAD.

从肺腺癌（LUAD）到小细胞肺癌（SCLC）的谱系转化是一种罕见但文献充分的脱靶机制，与对酪氨酸激酶抑制剂（TKIs）的获得性耐药相关。然而，这种转变与形态变化之间的关系仍然没有得到充分的了解。本研究旨在阐明RB1耗竭促进谱系转化的分子机制，特别强调其在形态改变中的作用。方法对体内和体外rb1缺失LUAD模型进行分子、形态学和结构分析。为了进一步阐明RB1/E2F1/HDAC1轴的作用机制，我们对RB1相关调节因子进行了功能扰动和药理抑制。结果低表达TP53和RB1的LUAD患者肿瘤侵袭特征增强，临床预后较差。我们的研究结果表明，RB1缺失诱导LUAD细胞的上皮-间质转化（EMT）特征，如纺锤状形态、vimentin表达增加和E-cadherin表达减少。此外，RB1的缺失导致核异常，包括核标志的不规则分布，如层粘连蛋白A/C和emerin，这有助于肿瘤的侵袭性。通过下调RB1/E2F1/HDAC1复合物的单个组分，我们发现HDAC1是影响层粘连蛋白a /C修饰和核变形的关键调控因子。药物抑制HDAC1衍生物可改善rb1缺失肺癌细胞中观察到的核异常，提示一种潜在的治疗策略。从机制上讲，乙酰化的纤层蛋白A/C的丢失导致其降解和颗粒状分布，导致核力学稳定性受损和细胞骨架动力学缺陷，这可能解释了所观察到的EMT。总之，我们的研究结果表明，RB1的下调通过hdac1介导的层粘胶蛋白A/C的去乙酰化促进EMT和核异常，从而显著影响LUAD的形态。未来的研究应优先开发旨在恢复RB1功能或抑制HDAC1的靶向治疗，以减缓癌症进展，从而加强tki耐药LUAD的患者分层和治疗策略。

{"title":"HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma","authors":"Hongxia Li , Yu Chen , Lihong Wei , Peng Wu , Fei Fang , Fengru Li , Bixia Liu , Shuhua Li , Qiong He , Jianwen Zhou , Kejing Tang , Zunfu Ke","doi":"10.1016/j.lungcan.2026.109301","DOIUrl":"10.1016/j.lungcan.2026.109301","url":null,"abstract":"<div><h3>Background</h3><div>Lineage transformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC) represents a rare yet well-documented off-target mechanism associated with acquired resistance to tyrosine kinase inhibitors (TKIs). However, the relationship between this transformation and morphological changes remains inadequately understood. This study seeks to elucidate the molecular mechanisms by which RB1 depletion facilitates lineage transformation, with a particular emphasis on its role in morphological alterations.</div></div><div><h3>Methods</h3><div>Integrated molecular, morphological, and structural analyses were conducted in RB1-deficient LUAD models in vitro and in vivo. Functional perturbation and pharmacological inhibition of RB1-associated regulators were further performed to delineate the mechanism of the RB1/E2F1/HDAC1 axis.</div></div><div><h3>Results</h3><div>Patients with LUAD exhibiting low expression levels of TP53 and RB1 exhibited enhanced tumor invasion characteristics and a poor clinical prognosis. Our findings demonstrated that RB1 depletion induced epithelial-mesenchymal transition (EMT) characteristics in LUAD cells, as evidenced by spindle-shaped morphology, increased vimentin expression, and decreased E-cadherin expression. Furthermore, RB1 loss is responsible for nuclear abnormalities, including irregular distribution of nuclear hallmarks such as lamin A/C and emerin, which contribute to tumor aggressiveness. Through the downregulation of individual components of the RB1/E2F1/HDAC1 complex, we identified HDAC1 as a key regulatory factor influencing lamin A/C modification and nuclear deformation. Pharmacological inhibition of HDAC1 derivatives ameliorates the nuclear abnormalities observed in RB1-depleted lung cancer cells, suggesting a potential therapeutic strategy. Mechanistically, the loss of acetylated lamin A/C leads to its degradation and granular distribution, resulting in compromised nuclear mechanostability and defective cytoskeletal dynamics, which may elucidate the observed EMT.</div></div><div><h3>Conclusions</h3><div>Collectively, our findings suggested that the downregulation of RB1 significantly influences the morphology of LUAD by facilitating EMT and nuclear abnormalities through HDAC1-mediated deacetylation of lamin A/C. Future research should prioritize the development of targeted therapies aimed at restoring RB1 function or inhibiting HDAC1 to mitigate cancer progression, thereby enhancing patient stratification and treatment strategies in TKI-resistant LUAD.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109301"},"PeriodicalIF":4.4,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146147572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis amivantamab + lazertinib与osimertinib作为一线治疗的亚洲egfr突变晚期NSCLC患者的总生存率：MARIPOSA亚群分析

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-04 DOI: 10.1016/j.lungcan.2026.109305

Hidetoshi Hayashi , Byoung Chul Cho , Yu Jung Kim , Se-Hoon Lee , Pongwut Danchaivijitr , Adlinda Alip , Hailin Xiong , Soon-Hin How , Gee-Chen Chang , James Chih-Hsin Yang , Yuta Yamanaka , Mehmet Ali Nahit Şendur , Kumar Prabhash , Koichi Azuma , Alianu Akawung , Elizabeth Fennema , Xiaodan Tang , Sujay Shah , Seema Sethi , Shun Lu

Background

Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line EGFR-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) analysis of MARIPOSA (NCT04487080), amivantamab-lazertinib showed a statistically significant and clinically meaningful improvement in OS versus osimertinib (HR, 0.75; P = 0.005) among all participants. We evaluated OS for amivantamab-lazertinib versus osimertinib in Asian participants.

Patients and methods

Participants with previously untreated EGFR-mutated, locally advanced/metastatic NSCLC were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib, or lazertinib (for evaluating contribution of components). Self-identified Asian race was a stratification factor. OS was a key secondary endpoint.

Results

Of 1074 randomized participants, 629 self-identified as Asian (amivantamab-lazertinib:250; osimertinib:251; lazertinib:128). At a median follow-up of 38.7 months, amivantamab-lazertinib significantly prolonged OS versus osimertinib among Asian participants. Median OS was not reached (NR; 95 % CI, NR–NR) for amivantamab-lazertinib versus 38.4 months (95 % CI, 35.1–NR) for osimertinib (HR, 0.74; 95 % CI, 0.56–0.97; nominal P = 0.026). Assuming exponential distribution of OS in both arms, amivantamab-lazertinib is projected to prolong median OS among Asian participants by > 12 months versus osimertinib. At 36 months, 61 % and 53 % were alive in the amivantamab-lazertinib and osimertinib arms. Safety profile was consistent with the overall population.

Conclusions

Consistent with the overall population, amivantamab-lazertinib significantly improved OS versus osimertinib among Asian participants with previously untreated EGFR-mutated advanced NSCLC, making it the first regimen to improve survival among Asian patients.

大约60%的肺癌病例发生在亚洲，这表明存在流行病学差异，需要有效的治疗方法。Amivantamab-lazertinib在许多国家被批准用于一线egfr突变的晚期非小细胞肺癌（NSCLC）。在方案指定的MARIPOSA （NCT04487080）的最终总生存期（OS）分析中，amivantamab-lazertinib在所有参与者中显示出与奥西替尼相比具有统计学意义和临床意义的OS改善（HR, 0.75; P = 0.005）。我们在亚洲参与者中评估了阿米万他单-拉泽替尼与奥西替尼的OS。患者和方法：先前未经治疗的egfr突变、局部晚期/转移性NSCLC患者以2:2:1的比例随机分配，分别接受阿米伐他麦-拉泽替尼、奥西替尼或拉泽替尼（用于评估各组分的贡献）。自我认同的亚洲种族是一个分层因素。操作系统是一个关键的次要终点。结果在1074名随机参与者中，629人自我认定为亚洲人（阿米伐他麦-拉泽替尼：250人；奥西替尼：251人；拉泽替尼：128人）。在38.7个月的中位随访中，阿米万他单-拉泽替尼与奥西替尼相比显著延长了亚洲参与者的生存期。amivantamab-lazertinib的中位OS未达到（NR; 95% CI, NR - NR），而osimertinib的中位OS为38.4个月（95% CI, 34.1 - NR）（HR, 0.74; 95% CI, 0.56-0.97；名义P = 0.026）。假设两组患者的OS呈指数分布，与奥西替尼相比，预计阿米万他单-拉泽替尼可使亚洲患者的中位OS延长12个月。在36个月时，阿米万他单-拉泽替尼组和奥西替尼组分别有61%和53%的患者存活。安全性与总体人群一致。与总体人群一致，amivantamab-lazertinib与osimertinib相比显著改善了先前未经治疗的egfr突变晚期NSCLC的亚洲参与者的OS，使其成为第一个改善亚洲患者生存的方案。

{"title":"Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis","authors":"Hidetoshi Hayashi , Byoung Chul Cho , Yu Jung Kim , Se-Hoon Lee , Pongwut Danchaivijitr , Adlinda Alip , Hailin Xiong , Soon-Hin How , Gee-Chen Chang , James Chih-Hsin Yang , Yuta Yamanaka , Mehmet Ali Nahit Şendur , Kumar Prabhash , Koichi Azuma , Alianu Akawung , Elizabeth Fennema , Xiaodan Tang , Sujay Shah , Seema Sethi , Shun Lu","doi":"10.1016/j.lungcan.2026.109305","DOIUrl":"10.1016/j.lungcan.2026.109305","url":null,"abstract":"<div><h3>Background</h3><div>Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line <em>EGFR</em>-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) analysis of MARIPOSA (NCT04487080), amivantamab-lazertinib showed a statistically significant and clinically meaningful improvement in OS versus osimertinib (HR, 0.75; <em>P</em> = 0.005) among all participants. We evaluated OS for amivantamab-lazertinib versus osimertinib in Asian participants.</div></div><div><h3>Patients and methods</h3><div>Participants with previously untreated <em>EGFR</em>-mutated, locally advanced/metastatic NSCLC were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib, or lazertinib (for evaluating contribution of components). Self-identified Asian race was a stratification factor. OS was a key secondary endpoint.</div></div><div><h3>Results</h3><div>Of 1074 randomized participants, 629 self-identified as Asian (amivantamab-lazertinib:250; osimertinib:251; lazertinib:128). At a median follow-up of 38.7 months, amivantamab-lazertinib significantly prolonged OS versus osimertinib among Asian participants. Median OS was not reached (NR; 95 % CI, NR–NR) for amivantamab-lazertinib versus 38.4 months (95 % CI, 35.1–NR) for osimertinib (HR, 0.74; 95 % CI, 0.56–0.97; nominal <em>P</em> = 0.026). Assuming exponential distribution of OS in both arms, amivantamab-lazertinib is projected to prolong median OS among Asian participants by > 12 months versus osimertinib. At 36 months, 61 % and 53 % were alive in the amivantamab-lazertinib and osimertinib arms. Safety profile was consistent with the overall population.</div></div><div><h3>Conclusions</h3><div>Consistent with the overall population, amivantamab-lazertinib significantly improved OS versus osimertinib among Asian participants with previously untreated <em>EGFR</em>-mutated advanced NSCLC, making it the first regimen to improve survival among Asian patients.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"214 ","pages":"Article 109305"},"PeriodicalIF":4.4,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychological features and quality of life in low-dose CT lung cancer screening: a comparative analysis with general population data 低剂量CT肺癌筛查的心理特征和生活质量：与普通人群数据的比较分析。

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-03 DOI: 10.1016/j.lungcan.2026.109307

Wei-Chia Huang , Tzu-Ning Kao , Shih-Cheng Liao , Mong-Wei Lin , Wei-Lieh Huang

Objective

Concerns persist regarding the psychological effects of low dose computed tomography (LDCT) screening, with prior studies linking it to psychological distress and diminished quality of life (QoL). However, specific risk factors remain unclear. This study aimed to compare the psychological features of LDCT recipients with the general population and identify associated factors.

Methods

A cross-sectional analysis was conducted using prospectively collected data from April 2022 to April 2023. Participants seeking second opinions at a tertiary medical center in Asia after LDCT screenings were recruited. We collected sociodemographic data, screening details, and self-administered questionnaires assessing somatic symptoms, health anxiety, depression, anxiety, and quality of life. Psychological conditions and QoL were compared between LDCT recipients and a general population cohort comprising 3161 individuals.

Results

We compared 201 LDCT recipients (30.8% male, mean age 56.6 years) with 3161 general population controls. Compared to the general population (adjusted for age and sex), LDCT recipients had significantly higher rates of somatic symptom disorder (28.9% vs. 5.0%, p < 0.001), depression (16.4% vs. 5.7%, p < 0.001), and anxiety (20.9% vs. 3.5%, p < 0.001). Among 103 participants undergoing surgical intervention, 85.4% were diagnosed with malignant or precancerous lesions. The 3-year overall survival rate was 98.0%, indicating favorable clinical outcomes.

Conclusion

LDCT recipients in an Asian population exhibited a higher prevalence of psychological distress than the general population. Close monitoring is essential, especially among those with pre-existing mental health issues. Future longitudinal studies are needed to elucidate long-term psychological outcomes of LDCT screening.

目的：低剂量计算机断层扫描（LDCT）筛查对心理的影响一直受到关注，之前的研究将其与心理困扰和生活质量（QoL）下降联系起来。然而，具体的风险因素仍不清楚。本研究旨在比较LDCT受者与一般人群的心理特征，并确定相关因素。方法：对2022年4月至2023年4月前瞻性收集的数据进行横断面分析。招募了在亚洲三级医疗中心接受LDCT筛查后寻求第二意见的参与者。我们收集了社会人口统计数据、筛选细节和自我管理的问卷，评估躯体症状、健康焦虑、抑郁、焦虑和生活质量。比较LDCT接受者和3161名普通人群的心理状况和生活质量。结果：我们比较了201例LDCT受者（30.8%为男性，平均年龄56.6岁）和3161例普通人群对照。与普通人群相比（根据年龄和性别进行调整），LDCT受者的躯体症状障碍发生率明显更高（28.9% vs. 5.0%）， p结论：亚洲人群中LDCT受者的心理困扰患病率高于普通人群。密切监测至关重要，特别是对那些已经存在精神健康问题的人。未来的纵向研究需要阐明LDCT筛查的长期心理结果。

{"title":"Psychological features and quality of life in low-dose CT lung cancer screening: a comparative analysis with general population data","authors":"Wei-Chia Huang , Tzu-Ning Kao , Shih-Cheng Liao , Mong-Wei Lin , Wei-Lieh Huang","doi":"10.1016/j.lungcan.2026.109307","DOIUrl":"10.1016/j.lungcan.2026.109307","url":null,"abstract":"<div><h3>Objective</h3><div>Concerns persist regarding the psychological effects of low dose computed tomography (LDCT) screening, with prior studies linking it to psychological distress and diminished quality of life (QoL). However, specific risk factors remain unclear. This study aimed to compare the psychological features of LDCT recipients with the general population and identify associated factors.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis was conducted using prospectively collected data from April 2022 to April 2023. Participants seeking second opinions at a tertiary medical center in Asia after LDCT screenings were recruited. We collected sociodemographic data, screening details, and self-administered questionnaires assessing somatic symptoms, health anxiety, depression, anxiety, and quality of life. Psychological conditions and QoL were compared between LDCT recipients and a general population cohort comprising 3161 individuals.</div></div><div><h3>Results</h3><div>We compared 201 LDCT recipients (30.8% male, mean age 56.6 years) with 3161 general population controls. Compared to the general population (adjusted for age and sex), LDCT recipients had significantly higher rates of somatic symptom disorder (28.9% vs. 5.0%, p < 0.001), depression (16.4% vs. 5.7%, p < 0.001), and anxiety (20.9% vs. 3.5%, p < 0.001). Among 103 participants undergoing surgical intervention, 85.4% were diagnosed with malignant or precancerous lesions. The 3-year overall survival rate was 98.0%, indicating favorable clinical outcomes.</div></div><div><h3>Conclusion</h3><div>LDCT recipients in an Asian population exhibited a higher prevalence of psychological distress than the general population. Close monitoring is essential, especially among those with pre-existing mental health issues. Future longitudinal studies are needed to elucidate long-term psychological outcomes of LDCT screening.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 109307"},"PeriodicalIF":4.4,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer 非小细胞肺癌中免疫细胞密度超出临床参数的增量预后价值。

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-03 DOI: 10.1016/j.lungcan.2026.108935

Love Nordling , Max Backman , Artur Mezheyeuski , Joakim Lindblad , Nataša Sladoje , Patrick Micke

Background

Multiplex immunofluorescence imaging enables detailed characterization of the tumor immune microenvironment, but whether immune cell densities add prognostic value beyond established clinical factors in non-small cell lung cancer (NSCLC) remains unclear.

Methods

Tissue samples from an NSCLC cohort (n = 298) were stained with a multiplex immunofluorescence panel targeting immune cell markers (CD4, CD8, FoxP3, CD20), cancer cells (pan-cytokeratin), and cell nuclei (DAPI). We quantified immune cell densities, nuclear pleomorphism features, and clinical variables, and trained four machine learning models (logistic regression, random forest, support vector machine, and k-nearest neighbors) to predict overall survival.

Results

Clinical parameters consistently demonstrated the strongest performance in predicting long and short-term survival (logistic regression mean accuracy 0.60 ± 0.01, AUC 0.66 ± 0.01). The addition of immune cell densities revealed a small, statistically significant improvement in survival prediction (accuracy 0.62 ± 0.01, p < 0.01, AUC 0.67 ± 0.01, p = 0.04), while nuclear pleomorphism features did not improve prediction. When combined with clinical parameters, immune cell densities also improved survival stratification in Cox regression analyses numerically (HR = 0.51 vs. 0.55 for clinical parameters alone). Model interpretation analyses showed that stage and performance status have the largest effect on model performance. Selected immune cell densities (tumor CD4-helper and stroma B-cells) have a limited but consistent effect.

Conclusion

Clinical parameters remain the dominant predictors of outcome in NSCLC, with immune cell densities providing only limited prognostic value for clinical stratification. The openly available code and datasets present a unique resource for method development or focused analysis.

背景：多重免疫荧光成像能够详细表征肿瘤免疫微环境，但在非小细胞肺癌（NSCLC）中，免疫细胞密度是否在确定的临床因素之外增加了预后价值尚不清楚。方法：采用针对免疫细胞标记物（CD4、CD8、FoxP3、CD20）、癌细胞（泛细胞角蛋白）和细胞核（DAPI）的多重免疫荧光面板对来自非小细胞肺癌队列（n = 298）的组织样本进行染色。我们量化了免疫细胞密度、核多形性特征和临床变量，并训练了四种机器学习模型（逻辑回归、随机森林、支持向量机和k近邻）来预测总生存率。结果：临床参数在预测长期和短期生存方面表现一致（logistic回归平均准确率0.60±0.01,AUC 0.66±0.01）。结论：临床参数仍然是NSCLC预后的主要预测因素，而免疫细胞密度对临床分层的预后价值有限。公开可用的代码和数据集为方法开发或重点分析提供了独特的资源。

{"title":"Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer","authors":"Love Nordling , Max Backman , Artur Mezheyeuski , Joakim Lindblad , Nataša Sladoje , Patrick Micke","doi":"10.1016/j.lungcan.2026.108935","DOIUrl":"10.1016/j.lungcan.2026.108935","url":null,"abstract":"<div><h3>Background</h3><div>Multiplex immunofluorescence imaging enables detailed characterization of the tumor immune microenvironment, but whether immune cell densities add prognostic value beyond established clinical factors in non-small cell lung cancer (NSCLC) remains unclear.</div></div><div><h3>Methods</h3><div>Tissue samples from an NSCLC cohort (n = 298) were stained with a multiplex immunofluorescence panel targeting immune cell markers (CD4, CD8, FoxP3, CD20), cancer cells (pan-cytokeratin), and cell nuclei (DAPI). We quantified immune cell densities, nuclear pleomorphism features, and clinical variables, and trained four machine learning models (logistic regression, random forest, support vector machine, and k-nearest neighbors) to predict overall survival.</div></div><div><h3>Results</h3><div>Clinical parameters consistently demonstrated the strongest performance in predicting long and short-term survival (logistic regression mean accuracy 0.60 ± 0.01, AUC 0.66 ± 0.01). The addition of immune cell densities revealed a small, statistically significant improvement in survival prediction (accuracy 0.62 ± 0.01, p < 0.01, AUC 0.67 ± 0.01, p = 0.04), while nuclear pleomorphism features did not improve prediction. When combined with clinical parameters, immune cell densities also improved survival stratification in Cox regression analyses numerically (HR = 0.51 vs. 0.55 for clinical parameters alone). Model interpretation analyses showed that stage and performance status have the largest effect on model performance. Selected immune cell densities (tumor CD4-helper and stroma B-cells) have a limited but consistent effect.</div></div><div><h3>Conclusion</h3><div>Clinical parameters remain the dominant predictors of outcome in NSCLC, with immune cell densities providing only limited prognostic value for clinical stratification. The openly available code and datasets present a unique resource for method development or focused analysis.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108935"},"PeriodicalIF":4.4,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis 阿米万他单抗加化疗与化疗对EGFR外显子20插入突变晚期非小细胞肺癌患者的一线治疗：PAPILLON亚洲亚组分析

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-02-02 DOI: 10.1016/j.lungcan.2026.109302

Caicun Zhou , Ke-Jing Tang , Baogang Liu , Sang-We Kim , Satoru Kitazono , Akira Ono , Muthukkumaran Thiagarajan , Jen-Yu Hung , Michael Boyer , Timuçin Çİl , Yu Yao , Rajnish Nagarkar , John Xie , Archan Bhattacharya , Honeylet Wortman-Vayn , Mahadi Baig , Trishala Agrawal , Patricia Lorenzini , Se-Hoon Lee , Byoung Chul Cho

Background

Amivantamab is a bispecific, epidermal growth factor receptor (EGFR) and MET-proto-oncogene (MET)-targeting antibody with immune cell-directing activity. In the global Phase 3 PAPILLON trial, amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) significantly improved progression-free survival (PFS) vs chemotherapy alone in previously untreated participants with locally advanced/metastatic NSCLC with EGFR exon 20 insertions (Ex20ins). We evaluated clinical outcomes in Asian participants in PAPILLON (NCT04538664).

Methods

Participants were randomized 1:1 to amivantamab-chemotherapy or chemotherapy alone. Study endpoints for this analysis were PFS by blinded independent central review (primary), objective response rate (ORR), duration of response (DoR), PFS after first subsequent therapy (PFS2), overall survival (OS), and safety (secondary). Crossover to amivantamab monotherapy was allowed when disease progressed on chemotherapy alone.

Results

Among 186 participants in the Asian sub-cohort, 97 received amivantamab-chemotherapy and 89 received chemotherapy. At median follow-up of 16.6 months, median PFS (95% confidence interval [CI]) in the amivantamab-chemotherapy/chemotherapy groups was 11.5/5.6 months (hazard ratio [HR] 0.34; 95%CI, 0.23–0.49; nominal p < 0.0001) arms. The ORR was 70% vs 51% (odds ratio 2.2, 95%CI, 1.2–3.9; nominal p = 0.012), DoR 10.1 vs 5.5 months. Median PFS2 was not estimable vs 18.8 months (HR 0.46, 95%CI 0.26–0.83; nominal p = 0.008), and median interim OS not estimable vs 24.4 months HR 0.65, 95%CI 0.34–1.24; nominal p = 0.189), respectively, despite substantial (73%) crossover. Safety profiles for both arms were similar to the overall PAPILLON population.

Conclusions

Amivantamab-chemotherapy demonstrated superior PFS vs chemotherapy and represents a new standard of care for first-line treatment of Asian participants with Ex20ins-mutated NSCLC.

背景：阿米万他抗是一种双特异性的表皮生长因子受体（EGFR）和MET原癌基因（MET）靶向抗体，具有免疫细胞定向活性。在全球3期PAPILLON试验中，amivantamab联合卡铂-培美曲塞（amivantamab-chemotherapy）显著改善了EGFR外显子20插入（Ex20ins）的局部晚期/转移性NSCLC患者的无进展生存期（PFS）。我们评估了PAPILLON （NCT04538664）在亚洲参与者中的临床结果。方法：参试者按1:1的比例随机分为阿米万他单化疗组和单独化疗组。该分析的研究终点为盲法独立中心评价的PFS（主要）、客观缓解率（ORR）、缓解持续时间（DoR）、首次后续治疗后的PFS （PFS2）、总生存期（OS）和安全性（次要）。当单独化疗的疾病进展时，允许交叉到阿米万他单药治疗。结果：在亚洲亚队列的186名参与者中，97名接受了阿米万他单化疗，89名接受了化疗。在中位随访16.6个月时，阿米万他抗化疗/化疗组的中位PFS（95%可信区间[CI]）为11.5/5.6个月（风险比[HR] 0.34; 95%CI, 0.23-0.49; nominal p）结论：阿米万他抗化疗比化疗显示出更优的PFS，代表了ex20in突变的亚洲非小细胞肺癌患者一线治疗的新标准。

{"title":"Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis","authors":"Caicun Zhou , Ke-Jing Tang , Baogang Liu , Sang-We Kim , Satoru Kitazono , Akira Ono , Muthukkumaran Thiagarajan , Jen-Yu Hung , Michael Boyer , Timuçin Çİl , Yu Yao , Rajnish Nagarkar , John Xie , Archan Bhattacharya , Honeylet Wortman-Vayn , Mahadi Baig , Trishala Agrawal , Patricia Lorenzini , Se-Hoon Lee , Byoung Chul Cho","doi":"10.1016/j.lungcan.2026.109302","DOIUrl":"10.1016/j.lungcan.2026.109302","url":null,"abstract":"<div><h3>Background</h3><div>Amivantamab is a bispecific, epidermal growth factor receptor (EGFR) and MET-proto-oncogene (MET)-targeting antibody with immune cell-directing activity. In the global Phase 3 PAPILLON trial, amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) significantly improved progression-free survival (PFS) vs chemotherapy alone in previously untreated participants with locally advanced/metastatic NSCLC with <em>EGFR</em> exon 20 insertions (Ex20ins). We evaluated clinical outcomes in Asian participants in PAPILLON (NCT04538664).</div></div><div><h3>Methods</h3><div>Participants were randomized 1:1 to amivantamab-chemotherapy or chemotherapy alone. Study endpoints for this analysis were PFS by blinded independent central review (primary), objective response rate (ORR), duration of response (DoR), PFS after first subsequent therapy (PFS2), overall survival (OS), and safety (secondary). Crossover to amivantamab monotherapy was allowed when disease progressed on chemotherapy alone.</div></div><div><h3>Results</h3><div>Among 186 participants in the Asian sub-cohort, 97 received amivantamab-chemotherapy and 89 received chemotherapy. At median follow-up of 16.6 months, median PFS (95% confidence interval [CI]) in the amivantamab-chemotherapy/chemotherapy groups was 11.5/5.6 months (hazard ratio [HR] 0.34; 95%CI, 0.23–0.49; nominal p < 0.0001) arms. The ORR was 70% vs 51% (odds ratio 2.2, 95%CI, 1.2–3.9; nominal p = 0.012), DoR 10.1 vs 5.5 months. Median PFS2 was not estimable vs 18.8 months (HR 0.46, 95%CI 0.26–0.83; nominal p = 0.008), and median interim OS not estimable vs 24.4 months HR 0.65, 95%CI 0.34–1.24; nominal p = 0.189), respectively, despite substantial (73%) crossover. Safety profiles for both arms were similar to the overall PAPILLON population.</div></div><div><h3>Conclusions</h3><div>Amivantamab-chemotherapy demonstrated superior PFS vs chemotherapy and represents a new standard of care for first-line treatment of Asian participants with Ex20ins-mutated NSCLC.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 109302"},"PeriodicalIF":4.4,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm 预防和管理阿米万他单抗引起的皮肤毒性：欧洲专家共识和实用算法。

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-01-30 DOI: 10.1016/j.lungcan.2026.108950

Nikolaou Vasiliki , Sibaud Vincent , Apalla Zoe , Starace Michela , Mayor Ander , Giacchero Damien , Sollena Pietro , Fattore Davide , Malissen Nausicaa

Background

Amivantamab, a bispecific antibody targeting EGFR and MET, is increasingly used in advanced non–small cell lung cancer. Dermatologic and mucosal adverse events are highly prevalent and often more severe and clinically complex than with conventional EGFR inhibitors, frequently challenging treatment continuation. However, structured management guidelines for amivantamab-associated toxicities are currently lacking.

Methods

An international panel of dermatologists with expertise in oncodermatology and members of the EADV Task Force “Dermatology for Cancer Patients” conducted a structured review of clinical trial data, emerging real-world evidence, and existing toxicity management frameworks. Key clinical challenges were identified through iterative expert discussions, and consensus was achieved through repeated rounds of manuscript review and refinement. Pragmatic grading systems and stepwise management algorithms were developed.

Results

We propose comprehensive strategies for prevention and monitoring and provide toxicity-specific management algorithms for acneiform eruption, erosive pustular dermatosis (EPD)-like scalp reactions, paronychia, anogenital ulcerations, and mucositis. For EPD-like scalp eruptions and anogenital ulcerations, where validated grading systems are lacking, we introduce pragmatic severity-based grading frameworks. Emphasis is placed on early recognition, individualized supportive care, appropriate use of systemic therapies, and timely treatment modification to minimize unnecessary interruptions while ensuring patient safety.

Conclusions

Amivantamab is associated with a distinctive and clinically impactful toxicity profile that frequently complicates routine management. These consensus-based recommendations provide thoracic oncologists with practical tools to support early intervention, optimized supportive care, and rational treatment adaptation, potentially improving quality of life, reducing avoidable treatment interruptions, and supporting sustained oncologic benefit.

背景：Amivantamab是一种靶向EGFR和MET的双特异性抗体，越来越多地用于晚期非小细胞肺癌。皮肤和粘膜不良事件非常普遍，通常比传统的EGFR抑制剂更严重和临床复杂，经常挑战治疗的持续。然而，目前缺乏针对阿米万他单相关毒性的结构化管理指南。方法：一个由肿瘤皮肤科专家和EADV“癌症患者皮肤科”工作组成员组成的国际小组对临床试验数据、新出现的现实世界证据和现有的毒性管理框架进行了结构化审查。通过反复的专家讨论确定了关键的临床挑战，并通过反复的手稿审查和改进达成了共识。开发了实用的分级系统和逐步管理算法。结果：我们提出了全面的预防和监测策略，并提供了针对痤疮疹、糜烂性脓疱性皮肤病（EPD）样头皮反应、甲沟炎、肛门生殖器溃疡和粘膜炎的毒性特异性管理算法。对于缺乏有效分级系统的epd样头皮疹和肛门生殖器溃疡，我们引入了实用的基于严重程度的分级框架。重点放在早期识别、个体化支持治疗、适当使用全身治疗和及时调整治疗，以尽量减少不必要的中断，同时确保患者安全。结论：阿米万他单抗具有独特的临床毒性，经常使常规治疗复杂化。这些基于共识的建议为胸科肿瘤学家提供了实用的工具，以支持早期干预，优化支持性护理和合理的治疗适应，潜在地提高生活质量，减少可避免的治疗中断，并支持持续的肿瘤益处。

{"title":"Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm","authors":"Nikolaou Vasiliki , Sibaud Vincent , Apalla Zoe , Starace Michela , Mayor Ander , Giacchero Damien , Sollena Pietro , Fattore Davide , Malissen Nausicaa","doi":"10.1016/j.lungcan.2026.108950","DOIUrl":"10.1016/j.lungcan.2026.108950","url":null,"abstract":"<div><h3>Background</h3><div>Amivantamab, a bispecific antibody targeting EGFR and MET, is increasingly used in advanced non–small cell lung cancer. Dermatologic and mucosal adverse events are highly prevalent and often more severe and clinically complex than with conventional EGFR inhibitors, frequently challenging treatment continuation. However, structured management guidelines for amivantamab-associated toxicities are currently lacking.</div></div><div><h3>Methods</h3><div>An international panel of dermatologists with expertise in oncodermatology and members of the EADV Task Force “Dermatology for Cancer Patients” conducted a structured review of clinical trial data, emerging real-world evidence, and existing toxicity management frameworks. Key clinical challenges were identified through iterative expert discussions, and consensus was achieved through repeated rounds of manuscript review and refinement. Pragmatic grading systems and stepwise management algorithms were developed.</div></div><div><h3>Results</h3><div>We propose comprehensive strategies for prevention and monitoring and provide toxicity-specific management algorithms for acneiform eruption, erosive pustular dermatosis (EPD)-like scalp reactions, paronychia, anogenital ulcerations, and mucositis. For EPD-like scalp eruptions and anogenital ulcerations, where validated grading systems are lacking, we introduce pragmatic severity-based grading frameworks. Emphasis is placed on early recognition, individualized supportive care, appropriate use of systemic therapies, and timely treatment modification to minimize unnecessary interruptions while ensuring patient safety.</div></div><div><h3>Conclusions</h3><div>Amivantamab is associated with a distinctive and clinically impactful toxicity profile that frequently complicates routine management. These consensus-based recommendations provide thoracic oncologists with practical tools to support early intervention, optimized supportive care, and rational treatment adaptation, potentially improving quality of life, reducing avoidable treatment interruptions, and supporting sustained oncologic benefit.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"213 ","pages":"Article 108950"},"PeriodicalIF":4.4,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre” [Lung Cancer 211 (2026) 108873 “间质性肺疾病和间质性肺异常患者的放疗结果：来自英国三级中心的不良事件和生存率”[肺癌211(2026)108873]的更正。

IF 4.4 2区医学 Q1 ONCOLOGY

Lung Cancer

Pub Date : 2026-01-30 DOI: 10.1016/j.lungcan.2026.108942

Sarah Bowen Jones , Gerard Gurumurthy , Conal Hayton , Ahmad Lodhi , Aqeel Umar , Corinne Faivre-Finn

引用次数: 0